Intellia Therapeutics, Inc. 8K

Intellia Therapeutics reported Q2 2026 results, positive Phase 3 data and regulatory plans for lonvo-z in HAE, advancement of nex-z ATTR trials with new genomic safety insights, and a cash runway projected into 2028 following an April 2026 equity raise.

On August 6, 2026, Intellia Therapeutics, Inc. reported its second quarter 2026 financial results and provided business updates, highlighting positive Phase 3 HAELO trial data for its lead CRISPR gene-editing candidate lonvoguran ziclumeran (lonvo-z) in hereditary angioedema, plans to submit and secure FDA acceptance of a biologics license application for lonvo-z in the second half of 2026 with a targeted U.S. commercial launch in the first half of 2027, progress in restarting and advancing Phase 3 MAGNITUDE and MAGNITUDE-2 trials for nexiguran ziclumeran (nex-z) in ATTR amyloidosis including new genomic insights linked to liver enzyme elevations in patients with a specific HLA allele, and a strengthened cash position of approximately $628 million following an April 2026 equity offering, which is expected to fund operations at least into 2028 despite continuing net losses.

Filing Facts

CIK

1652130

Ticker

NTLA

Form

8K

Source Type

fda

Accession

0001193125-26-336772

Alert Tier

7